title: Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
abstract: BACKGROUND
  Tumor genetic features reported to correlate with adverse outcome in Wilms tumor include karyotype complexity, losses of material from the short arm of chromosome 1 and from the long arms of chromosomes 11, 16 and 22 and gain of material from the long arm of chromosome 1. This study sought to test these associations in a large series of tumors studied by cytogenetic analysis. Identification of markers associated with elevated risk of relapse and fatal outcome could allow more effective treatment stratification at presentation.
  
  
  METHODS
  Thirteen member laboratories of the U.K. Cancer Cytogenetics Group provided results from a 12-year period. Karyotype abnormalities were correlated with clinical data (age, tumor stage, and histology) and outcome data provided by the central register of the U.K. Children's Cancer Study Group.
  
  
  RESULTS
  Of 127 abnormal karyotypes, 78 included a reputedly "poor prognosis" feature. Univariate survival analysis showed no significant adverse effect for karyotype complexity, 1p loss or 11q loss. The poor outcome of cases with 16q loss was of borderline significance, but this effect was restricted to those tumors with unbalanced translocation der(16)t(1q;16q). The association between relapse risk and gain of 1q material was not significant. Only monosomy 22 was a significant marker of poor outcome in univariate analysis (13 cases showing 50% relapse free survival at 5 years compared to 79% survival for the remaining 114 cases, P = 0.02). In multivariate analysis, significant independent predictors of poor outcome were 1q gain (Hazard Ratio 3.4), stage IV disease (HR 5.0), and monosomy 22 (HR 5.9).
  
  
  CONCLUSIONS
  Loss of chromosome 22 identifies high risk Wilms tumors. The prognostic significance of 1q gain, 16q loss and unbalanced translocation der(16)t(1q;16q) is unresolved and warrants further investigation.
authors.affiliation: School of Biochemistry and Genetics, University of Newcastle upon Tyne, United Kingdom. Nick.Brown@ncl.ac.uk
authors.forename: Nick
authors.initials: N
authors.lastname: Bown
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Cotterill
authors.forename: Paul
authors.initials: P
authors.lastname: Roberts
authors.forename: Mike
authors.initials: M
authors.lastname: Griffiths
authors.forename: Simon
authors.initials: S
authors.lastname: Larkins
authors.forename: Steve
authors.initials: S
authors.lastname: Hibbert
authors.forename: Helen
authors.initials: H
authors.lastname: Middleton
authors.forename: Anna
authors.initials: A
authors.lastname: Kelsey
authors.forename: Denise
authors.initials: D
authors.lastname: Tritton
authors.forename: Chris
authors.initials: C
authors.lastname: Mitchell
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D002878:Chromosomes, Human, Pair 1; D002880:Chromosomes, Human, Pair 11; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005260:Female; D005819:Genetic Markers; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D009006:Monosomy; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D016019:Survival Analysis; D006113:United Kingdom; D009396:Wilms Tumor / Q000235:genetics* / Q000401:mortality / Q000473:pathology
chemical_list: D005819:Genetic Markers